Key Highlights

• Decoy Therapeutics (NASDAQ: DCOY) closed a $3.5 million private placement at $5.91 per share.

• The deal includes milestone-based warrants potentially unlocking up to $17.5 million in additional funding.

• Investors received Series A, B, and C warrants tied to clinical and regulatory milestones.

• Stockholder approval is required for warrant exercise, with a special meeting planned within 90 days.

Decoy Therapeutics (NASDAQ: DCOY) has finalized a private investment in public equity (PIPE) deal, raising immediate capital while structuring future funding tied to clinical progress. The agreement reflects growing investor confidence in the biotech’s pipeline, despite its micro-cap status.

Deal Structure and Terms

The company sold 592,217 shares of common stock at $5.91 per share, generating approximately $3.5 million in gross proceeds. Investors also received pre-funded warrants as an alternative, priced at $5.91 minus $0.0001 per share, ensuring minimal upfront cost for future equity access.

Milestone Warrants Unlocked

Alongside the shares, buyers secured Series A, B, and C warrants, each exercisable at $5.91 per share. These warrants cover 100%, 200%, and 200% of the purchased shares, respectively, potentially adding up to $17.5 million if all milestones are met. The warrants are tied to regulatory and clinical achievements, including Phase 1 and Phase 2a trial approvals.

Stockholder Approval Required

The warrants remain unexercisable until Decoy Therapeutics obtains stockholder approval, a Nasdaq compliance requirement. The company committed to holding a special meeting within 90 days of the June 29 closing date to secure this approval, with follow-up votes every 90 days if needed.

Ownership and Lock-Up Provisions

Investors face a 4.99% beneficial ownership cap, extendable to 9.99% with prior notice. The agreement also restricts the company from issuing additional common stock or equivalents under variable-rate transactions for 180 days post-closing, with limited exceptions.

Clinical and Financial Strategy

Proceeds will fund general corporate needs, with a focus on advancing Decoy’s lead asset into clinical trials. The milestone-based structure aligns investor returns with the company’s regulatory and developmental progress, reducing near-term dilution risks.

Warrant Expiry and Adjustments

Pre-funded warrants carry a nominal $0.0001 exercise price and no expiry, while milestone warrants expire 90 days after their triggering event or by June 26, 2031. Both warrant types include standard anti-dilution protections for stock splits or dividends.

Registration Rights Agreement

Decoy Therapeutics agreed to file a resale registration statement with the SEC within 15 days, covering shares and warrant-exercisable stock. The move ensures liquidity for investors while complying with regulatory requirements.

 

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.